NasdaqCM - Nasdaq Real Time Price USD

Akebia Therapeutics, Inc. (AKBA)

Compare

1.8900

+0.0200

+(1.07%)

At close: 4:00:01 PM EST

1.9100

+0.02

+(1.06%)

After hours: 6:05:14 PM EST

Akebia announces ‘multiple positive business updates’

Akebia (AKBA) Therapeutics announced multiple positive business updates. As of January, Vafseo tablets are available in the U.S. for adult patients with anemia due to chronic kidney disease on dialysis for at least three months, and shipment of product to dialysis centers has commenced. In addition, Akebia recently signed a Vafseo commercial supply agreement with a leading dialysis organization. Akebia now has contracts in place with dialysis organizations caring for nearly 100% of dialysis pati

TipRanks 10 hours ago

AKBA
+1.07%
Akebia Therapeutics Announces Multiple Positive Business Updates

Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced multiple positive business updates. As of January, Vafseo® (vadadustat) tablets are available in the U.S. for adult patients with anemia due to chronic kidney disease (CKD) on dialysis for at least three months, and shipment of product to dialysis centers has commenced. In addition, Akebia recently signed a Vafseo commercial supply agre

PR Newswire yesterday

AKBA
+1.07%
New Strong Sell Stocks for January 3rd

AKBA, KOF and GES have been added to the Zacks Rank #24 (Strong Sell) List on January 3, 2024.

Zacks 11 days ago

AKBA
+1.07%
KOF
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted one newly-hired employee options to purchase an aggregate of 3,000 shares of Akebia's common stock on December 31, 2024. The options were granted as an inducement material to the employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

PR Newswire 12 days ago

AKBA
+1.07%
High Growth Tech Stocks To Watch In December 2024

Over the last 7 days, the United States market has dropped 3.5%, yet it remains up by 22% over the past year with earnings forecasted to grow by 15% annually. In this context, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability to capitalize on these positive earnings forecasts despite recent market volatility.

Simply Wall St. 25 days ago

AKBA
+1.07%
ALDX
-1.47%
INFN
Investors in Akebia Therapeutics (NASDAQ:AKBA) have unfortunately lost 73% over the last five years

Akebia Therapeutics, Inc. ( NASDAQ:AKBA ) shareholders will doubtless be very grateful to see the share price up 31% in...

Simply Wall St. 25 days ago

AKBA
+1.07%
Akebia Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2024 at 7:30 AM PST. Among other business updates, Mr. Butler will discuss the Vafseo® (vadadustat) U.S. launch.

PR Newswire 27 days ago

AKBA
+1.07%
New Strong Sell Stocks for December 5th

AKBA, KOF and XRAY have been added to the Zacks Rank #5 (Strong Sell) List on December 5, 2024.

Zacks last month

AKBA
+1.07%
KOF
U.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo® (vadadustat) for CKD Patients on Dialysis

Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, announced that in late November U.S. Renal Care (USRC) enrolled the first patient in its Vafseo® (vadadustat) Outcomes In-Center Experience (VOICE) collaborative trial. Akebia announced the collaborative trial initiation in September 2024.

PR Newswire last month

AKBA
+1.07%
New Strong Sell Stocks for November 27th

AKBA, ABG and CLH have been added to the Zacks Rank #5 (Strong Sell) List on November 27, 2024.

Zacks last month

AKBA
+1.07%
ABG
Akebia Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference

Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will participate in a Fireside Discussion at the 36th Annual Piper Sandler Healthcare Conference on Tuesday, December 3rd at 10:30 AM EST.

PR Newswire last month

AKBA
+1.07%
Vadadustat Alternative Dosing Study Results Published in the American Journal of Kidney Disease

Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the American Journal of Kidney Disease has published the results of FO2CUS, an open-label study evaluating the efficacy and safety of vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor, in hemodialysis patients who were converted from a long-acting erythropoiesis-stimulating agent (ESA) to three time

PR Newswire last month

AKBA
+1.07%
Akebia Therapeutics to Present at the Jefferies London Healthcare Conference

Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will present at the Jefferies London Healthcare Conference on Thursday, November 21 at 1:00 PM GMT.

PR Newswire 2 months ago

AKBA
+1.07%
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$5.50

Akebia Therapeutics, Inc. ( NASDAQ:AKBA ) missed earnings with its latest quarterly results, disappointing...

Simply Wall St. 2 months ago

AKBA
+1.07%
Akebia Therapeutics Inc (AKBA) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges ...

Despite a decline in revenue, Akebia Therapeutics Inc (AKBA) focuses on strategic initiatives for Vafseo's market entry and maintaining financial stability.

GuruFocus.com 2 months ago

AKBA
+1.07%
Akebia Therapeutics (AKBA) Reports Q3 Loss, Misses Revenue Estimates

Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -100% and 18.03%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 2 months ago

AKBA
+1.07%
Akebia Therapeutics: Q3 Earnings Snapshot

CAMBRIDGE, Mass. AP) — Akebia Therapeutics Inc. AKBA) on Thursday reported a loss of $20 million in its third quarter.

Associated Press Finance 2 months ago

AKBA
+1.07%
Akebia Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today reported financial results for the third quarter ended September 30, 2024, and recent business highlights. During the quarter, Akebia continued to execute on the commercial launch of Vafseo® (vadadustat) to prepare for U.S. market availability expected in January 2025.

PR Newswire 2 months ago

AKBA
+1.07%
Akebia Therapeutics to Report Third Quarter 2024 Financial Results and Discuss Recent Business Highlights

Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the third quarter ended September 30, 2024, on Thursday, November 7, 2024, prior to the open of financial markets.

PR Newswire 2 months ago

AKBA
+1.07%
High Growth Tech Stocks to Watch in October 2024

The United States market has experienced a flat performance over the past week, although it has risen by 37% over the last 12 months, with earnings forecasted to grow by 15% annually. In this context, identifying high growth tech stocks involves focusing on companies that demonstrate strong innovation and adaptability to capitalize on these favorable market conditions.

Simply Wall St. 2 months ago

BILI

BLBLF

IBTA

Performance Overview

Return	AKBA	S&P 500
YTD	+2.16%	-1.08%
1-Year	+21.94%	+22.14%
3-Year	-11.27%	+25.41%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Akebia Therapeutics, Inc. (AKBA)

Akebia announces ‘multiple positive business updates’

Akebia Therapeutics Announces Multiple Positive Business Updates

New Strong Sell Stocks for January 3rd

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

High Growth Tech Stocks To Watch In December 2024

Investors in Akebia Therapeutics (NASDAQ:AKBA) have unfortunately lost 73% over the last five years

Akebia Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

New Strong Sell Stocks for December 5th

U.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo® (vadadustat) for CKD Patients on Dialysis

New Strong Sell Stocks for November 27th

Akebia Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference

Vadadustat Alternative Dosing Study Results Published in the American Journal of Kidney Disease

Akebia Therapeutics to Present at the Jefferies London Healthcare Conference

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$5.50

Akebia Therapeutics Inc (AKBA) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges ...

Akebia Therapeutics (AKBA) Reports Q3 Loss, Misses Revenue Estimates

Akebia Therapeutics: Q3 Earnings Snapshot

Akebia Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Akebia Therapeutics to Report Third Quarter 2024 Financial Results and Discuss Recent Business Highlights

High Growth Tech Stocks to Watch in October 2024

Performance Overview